Cargando…

Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy

Direct-acting antiviral (DAA) therapy has changed the landscape of hepatitis C virus (HCV) management and has changed the focus to the possibility of HCV elimination in the near future. Glecaprevir, an NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibitor, have addressed many of the exi...

Descripción completa

Detalles Bibliográficos
Autores principales: Cotter, Thomas G, Jensen, Donald M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681154/
https://www.ncbi.nlm.nih.gov/pubmed/31534310
http://dx.doi.org/10.2147/DDDT.S172512
_version_ 1783441666731933696
author Cotter, Thomas G
Jensen, Donald M
author_facet Cotter, Thomas G
Jensen, Donald M
author_sort Cotter, Thomas G
collection PubMed
description Direct-acting antiviral (DAA) therapy has changed the landscape of hepatitis C virus (HCV) management and has changed the focus to the possibility of HCV elimination in the near future. Glecaprevir, an NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibitor, have addressed many of the existing shortcomings in the DAA therapy spectrum. This combination has proven to be a highly efficacious pan-genotypic DAA with a high barrier to resistance as a once-daily, all-oral medication. This review explores the design and development of glecaprevir and pibrentasvir, its place in current HCV management in the midst of a myriad of DAA therapy options, and also remaining challenges.
format Online
Article
Text
id pubmed-6681154
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-66811542019-09-18 Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy Cotter, Thomas G Jensen, Donald M Drug Des Devel Ther Review Direct-acting antiviral (DAA) therapy has changed the landscape of hepatitis C virus (HCV) management and has changed the focus to the possibility of HCV elimination in the near future. Glecaprevir, an NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibitor, have addressed many of the existing shortcomings in the DAA therapy spectrum. This combination has proven to be a highly efficacious pan-genotypic DAA with a high barrier to resistance as a once-daily, all-oral medication. This review explores the design and development of glecaprevir and pibrentasvir, its place in current HCV management in the midst of a myriad of DAA therapy options, and also remaining challenges. Dove 2019-07-29 /pmc/articles/PMC6681154/ /pubmed/31534310 http://dx.doi.org/10.2147/DDDT.S172512 Text en © 2019 Cotter and Jensen. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Cotter, Thomas G
Jensen, Donald M
Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy
title Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy
title_full Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy
title_fullStr Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy
title_full_unstemmed Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy
title_short Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy
title_sort glecaprevir/pibrentasvir for the treatment of chronic hepatitis c: design, development, and place in therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681154/
https://www.ncbi.nlm.nih.gov/pubmed/31534310
http://dx.doi.org/10.2147/DDDT.S172512
work_keys_str_mv AT cotterthomasg glecaprevirpibrentasvirforthetreatmentofchronichepatitiscdesigndevelopmentandplaceintherapy
AT jensendonaldm glecaprevirpibrentasvirforthetreatmentofchronichepatitiscdesigndevelopmentandplaceintherapy